1
|
Nelson V, Ziehr J, Agulnik M and Johnson
M: Afatinib: Emerging next-generation tyrosine kinase inhibitor for
NSCLC. Onco Targets Ther. 6:135–143. 2013.PubMed/NCBI
|
2
|
Köhler J and Schuler M: Afatinib,
erlotinib and gefitinib in the first-line therapy of egfr
mutation-positive lung adenocarcinoma: A review. Onkologie.
36:510–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Health Quality Ontario, . Epidermal Growth
Factor Receptor Mutation (EGFR) testing for prediction of response
to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) drugs in patients
with advanced non-small-cell lung cancer: An evidence-based
analysis. Ont Health Technol Assess Ser. 10:1–48. 2010.
|
4
|
Shepherd FA, Pereira J Rodrigues, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Goldstraw P: Staging Manual in Thoracic
Oncology. Editorial Rx Press; Orange Park, FL: 2009, View Article : Google Scholar
|
6
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Karam I and Melosky B: Response to
second-line erlotinib in an EGFR mutation-negative patient with
non-small-cell lung cancer: Make no assumptions. Curr Oncol.
19:42–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Dudek AZ, Kmak KL, Koopmeiners J and
Keshtgarpour M: Skin rash and bronchoalveolar histology correlates
with clinical benefit in patients treated with gefitinib as a
therapy for previously treated advanced or metastatic non-small
cell lung cancer. Lung Cancer. 51:89–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Schumann C, Heigener D, Dittrich I,
Abenhardt W, Dederke B, Duell T, et al: Long term benefit from
erlotinib treatment is independent of prognostic factors and
therapeutic response (abstract 9146). Eur J Cancer. 7:12009.
|
10
|
Polychronidou G and Papakotoulas P:
Long-term treatment with erlotinib for EGFR wild-type non-small
cell lung cancer: A case report. Case Rep Oncol. 6:189–196. 2013.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Jeong HS, Jones D, Liao S, Wattson DA, Cui
CH, Duda DG, Willett CG, Jain RK and Padera TP: Investigation of
the lack of angiogenesis in the formation of lymph node metastases.
J Natl Cancer Inst. 107(pii): djv1552015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Markiewicz A, Książkiewicz M, Seroczyńska
B, Skokowski J, Szade J, Welnicka-Jaskiewicz M, Wełnicka-Jaśkiewicz
M and Zaczek AJ: Heterogeneity of mesenchymal markers
expression-molecular profiles of cancer cells disseminated by
lymphatic and hematogenous routes in breast cancer. Cancers.
5:1485–1503. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Augustin A, Lamerz J, Meistermann H,
Colling S, Scheiblich S, Hermann JC, Duchateau-Nguyen G, Tzouros M,
Avila DW, Langen H, et al: Quantitative chemical proteomics
profiling differentiates erlotinib from gefitinib in EGFR wild-type
non-small cell lung carcinoma cell lines. Mol Cancer Ther.
12:520–529. 2013. View Article : Google Scholar : PubMed/NCBI
|